Icosavax: Positive Topline Interim Phase 1 Results for Vaccine Against RSV, metapneumovirus

 IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults –

–  IVX-A12 was generally well tolerated with no vaccine-related SAEs –

–  First demonstration of hMPV vaccine immunogenicity in an older adult population –

–  No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology –

–  Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 in mid-2023, to be followed by an hMPV human challenge study as proof-of-concept efficacy study –

–  Concurrent $67.8 million registered direct offering; extends cash runway into 2H 2025 –

–  Company to host conference call/webcast today at 6:00 p.m. ET / 3:00 p.m. PT –

Icosavax will host a corresponding conference call and live webcast at 6:00 p.m. ET / 3:00 p.m. PT on May 22, 2023 to discuss the topline interim Phase 1 results for IVX-A12. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.icosavax.com. A webcast replay will be available in the investor relations section on the company’s website for 30 days following the completion of the call.

https://finance.yahoo.com/news/icosavax-announces-positive-topline-interim-213700632.html